Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

SOM signs licensing agreement with University of Minnesota to support muscular dystrophy work

May 16, 2022

MuSK-CAARTs demonstrate promising safety and activity in models of MuSK myasthenia gravis

May 16, 2022

Kymera presents preclinical data on STAT3 degrader KTX-115

May 13, 2022

Johns Hopkins University synthesizes MAP3K12/13 inhibitors

May 13, 2022

Myrtelle launches new research program for Pelizaeus-Merzbacher disease

May 12, 2022

Inflammation is key to preventing chronic pain, study finds

May 12, 2022

Incannex's IHL-216A shows neuroprotective effect in rodent model of sports concussion

May 11, 2022

NodThera announces addition of third NLRP3 inflammasome inhibitor to pipeline

May 11, 2022

AC Immune synthesizes MAPT aggregation inhibitors

May 11, 2022

Proline links gut microbiome to depression

May 9, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
NTX-819, a novel mGlu7 NAM for psychiatric disorders
BioWorld Science
Increasing evidence supports metabotropic glutamate mGlu7 receptor as a promising target in psychiatric disorders. Neurosterix Pharma Sarl has presented data on...